disulfiram has been researched along with Liver Neoplasms in 19 studies
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results showed that disulfiram enhanced sensitivity of human hepatocellular carcinoma cells to doxorubicin by 15-27-fold, and increased reactive oxygen species (ROS) production as well as caspase-dependent apoptosis." | 8.12 | Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways. ( Fang, Z; Guo, X; Li, M; Li, T; Liang, M; Lin, H; Sun, F; Zhang, Y; Zhou, X, 2022) |
| " One such anti-alcoholic drug, disulfiram, with significant anti-cancer potential was studied for its efficacy against Hep3B cell lines, an in vitro model of hepatocellular carcinoma." | 7.83 | Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line. ( Hoda, M; Mohankumar, K; Pajaniradje, S; Rajagopalan, R; Shakya, G, 2016) |
| " In the present study, we investigated the effect of disulfiram (DSF), an inhibitor of aldehyde dehydrogenase, toward tumor-initiating hepatocellular carcinoma (HCC) cells." | 7.80 | Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. ( Chiba, T; Hayashi, T; Iwama, A; Kaneko, S; Koide, S; Miyagi, S; Miyazaki, M; Motoyama, T; Nakatsura, T; Ogasawara, S; Ooka, Y; Oshima, M; Saraya, A; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O; Yuki, K; Zen, Y, 2014) |
| "Disulfiram (DSF) has copper (Cu)-dependent anticancer properties in vitro and in vivo." | 5.48 | Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways. ( Li, TY; Li, Y; Liu, S; Wang, LH; Wang, YT; Wu, CF; Yang, JY; Yuan, XZ; Zhang, HT; Zhou, WL, 2018) |
| "The results showed that disulfiram enhanced sensitivity of human hepatocellular carcinoma cells to doxorubicin by 15-27-fold, and increased reactive oxygen species (ROS) production as well as caspase-dependent apoptosis." | 4.12 | Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways. ( Fang, Z; Guo, X; Li, M; Li, T; Liang, M; Lin, H; Sun, F; Zhang, Y; Zhou, X, 2022) |
| " One such anti-alcoholic drug, disulfiram, with significant anti-cancer potential was studied for its efficacy against Hep3B cell lines, an in vitro model of hepatocellular carcinoma." | 3.83 | Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line. ( Hoda, M; Mohankumar, K; Pajaniradje, S; Rajagopalan, R; Shakya, G, 2016) |
| " In the present study, we investigated the effect of disulfiram (DSF), an inhibitor of aldehyde dehydrogenase, toward tumor-initiating hepatocellular carcinoma (HCC) cells." | 3.80 | Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. ( Chiba, T; Hayashi, T; Iwama, A; Kaneko, S; Koide, S; Miyagi, S; Miyazaki, M; Motoyama, T; Nakatsura, T; Ogasawara, S; Ooka, Y; Oshima, M; Saraya, A; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O; Yuki, K; Zen, Y, 2014) |
| "Disulfiram and metals inactivate key oncoproteins resulting in anti-neoplastic activity." | 3.01 | A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. ( Agarwal, N; Akerley, WL; Boucher, KM; Brittain-Blankenship, M; Buys, SS; Grossman, KF; Kelley, KC; Kennedy, TP; Kosak, KM; McGregor, KA; Sborov, DW; Shami, PJ; Sharma, S; Terrazas, MC; Thorne, KM; Ward, JH; Weis, JR; Werner, TL, 2021) |
| "Disulfiram (DSF) has copper (Cu)-dependent anticancer properties in vitro and in vivo." | 1.48 | Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways. ( Li, TY; Li, Y; Liu, S; Wang, LH; Wang, YT; Wu, CF; Yang, JY; Yuan, XZ; Zhang, HT; Zhou, WL, 2018) |
| "Cu2+ toxicity was examined in two hepatocellular carcinoma cell lines, HepG2 and Hep3B, with Hep3B cells containing an integrated hepatitis B virus genome." | 1.35 | Regulation of heme synthesis and proteasomal activity by copper: possible implications for Wilson's disease. ( Babushkin, T; Hait-Darshan, R; Malik, Z, 2009) |
| "Extracts of the hepatoma cells contained an enzymatic activity with an isoelectric point similar to that of ALDH1." | 1.29 | The novel aldehyde dehydrogenase gene, ALDH5, encodes an active aldehyde dehydrogenase enzyme. ( Crabb, DW; Dipple, KM; Malek, K; Stewart, MJ; Xiao, Q, 1995) |
| " DENA, which was administered to 38 rats in a dosage of 20 mg/kg/week, induced liver tumors in 90% of the animals; in 29% besides some precancerous stages predominantly malignant carcinomas of the oesophagus were seen." | 1.26 | Influence of disulfiram on the organotropy of the carcinogenic effect of dimethylnitrosamine and diethylnitrosamine in rats. ( Diehl, B; Habs, M; Krüger, FW; Schmähl, D, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Ren, X | 1 |
| Li, Y | 2 |
| Zhou, Y | 1 |
| Hu, W | 1 |
| Yang, C | 2 |
| Jing, Q | 1 |
| Zhou, C | 1 |
| Wang, X | 2 |
| Hu, J | 1 |
| Wang, L | 1 |
| Yang, J | 1 |
| Wang, H | 1 |
| Xu, H | 1 |
| Li, H | 1 |
| Tong, X | 1 |
| Wang, Y | 1 |
| Du, J | 1 |
| Lin, H | 1 |
| Sun, F | 1 |
| Li, T | 1 |
| Zhang, Y | 1 |
| Guo, X | 1 |
| Li, M | 1 |
| Liang, M | 1 |
| Zhou, X | 1 |
| Fang, Z | 1 |
| Kelley, KC | 1 |
| Grossman, KF | 1 |
| Brittain-Blankenship, M | 1 |
| Thorne, KM | 1 |
| Akerley, WL | 1 |
| Terrazas, MC | 1 |
| Kosak, KM | 1 |
| Boucher, KM | 1 |
| Buys, SS | 1 |
| McGregor, KA | 1 |
| Werner, TL | 1 |
| Agarwal, N | 1 |
| Weis, JR | 1 |
| Sharma, S | 1 |
| Ward, JH | 1 |
| Kennedy, TP | 2 |
| Sborov, DW | 1 |
| Shami, PJ | 1 |
| Read, E | 1 |
| Milford, J | 1 |
| Zhu, J | 1 |
| Wu, L | 1 |
| Bilodeau, M | 1 |
| Yang, G | 1 |
| Wang, LH | 1 |
| Zhang, HT | 1 |
| Wang, YT | 1 |
| Liu, S | 1 |
| Zhou, WL | 1 |
| Yuan, XZ | 1 |
| Li, TY | 1 |
| Wu, CF | 1 |
| Yang, JY | 1 |
| Hassan, I | 1 |
| Ebaid, H | 1 |
| Alhazza, IM | 1 |
| Al-Tamimi, J | 1 |
| Aman, S | 1 |
| Abdel-Mageed, AM | 1 |
| Chiba, T | 1 |
| Suzuki, E | 1 |
| Yuki, K | 1 |
| Zen, Y | 1 |
| Oshima, M | 1 |
| Miyagi, S | 1 |
| Saraya, A | 1 |
| Koide, S | 1 |
| Motoyama, T | 1 |
| Ogasawara, S | 1 |
| Ooka, Y | 1 |
| Tawada, A | 1 |
| Nakatsura, T | 1 |
| Hayashi, T | 1 |
| Yamashita, T | 1 |
| Kaneko, S | 1 |
| Miyazaki, M | 1 |
| Iwama, A | 1 |
| Yokosuka, O | 1 |
| Huang, H | 1 |
| Liao, Y | 1 |
| Liu, N | 1 |
| Hua, X | 1 |
| Cai, J | 1 |
| Long, H | 1 |
| Zhao, C | 1 |
| Chen, X | 1 |
| Lan, X | 1 |
| Zang, D | 1 |
| Wu, J | 1 |
| Li, X | 1 |
| Shi, X | 1 |
| Liu, J | 1 |
| Hoda, M | 1 |
| Pajaniradje, S | 1 |
| Shakya, G | 1 |
| Mohankumar, K | 1 |
| Rajagopalan, R | 1 |
| Wang, Z | 1 |
| Tan, J | 1 |
| McConville, C | 1 |
| Kannappan, V | 1 |
| Tawari, PE | 1 |
| Brown, J | 1 |
| Ding, J | 1 |
| Armesilla, AL | 1 |
| Irache, JM | 1 |
| Mei, QB | 1 |
| Tan, Y | 1 |
| Liu, Y | 1 |
| Jiang, W | 1 |
| Bian, XW | 1 |
| Wang, W | 1 |
| Goto, K | 1 |
| Kato, N | 1 |
| Chung, RT | 1 |
| Hait-Darshan, R | 1 |
| Babushkin, T | 1 |
| Malik, Z | 1 |
| Brar, SS | 1 |
| Grigg, C | 1 |
| Wilson, KS | 1 |
| Holder, WD | 1 |
| Dreau, D | 1 |
| Austin, C | 1 |
| Foster, M | 1 |
| Ghio, AJ | 1 |
| Whorton, AR | 1 |
| Stowell, GW | 1 |
| Whittall, LB | 1 |
| Whittle, RR | 1 |
| White, DP | 1 |
| Hadjiolov, D | 1 |
| Frank, N | 1 |
| Mundt, D | 1 |
| Spiegelhalder, B | 1 |
| Wiessler, M | 1 |
| Schmähl, D | 2 |
| Stewart, MJ | 1 |
| Malek, K | 1 |
| Xiao, Q | 1 |
| Dipple, KM | 1 |
| Crabb, DW | 1 |
| Krüger, FW | 1 |
| Habs, M | 1 |
| Diehl, B | 1 |
| Van Duuren, BL | 1 |
| Chieco, P | 1 |
| Normanni, P | 1 |
| Moslen, MT | 1 |
| Maltoni, C | 1 |
| Gershbein, LL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver[NCT00742911] | Phase 1 | 21 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for disulfiram and Liver Neoplasms
| Article | Year |
|---|---|
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
Topics: Adult; Aged; Aged, 80 and over; Disulfiram; Dose-Response Relationship, Drug; Female; Gluconates; Gl | 2021 |
18 other studies available for disulfiram and Liver Neoplasms
| Article | Year |
|---|---|
Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Copper; Disulfiram; Ferroptosis; Humans; Kelch-Like ECH | 2021 |
Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Disulfiram; Doxorubicin; | 2022 |
The interaction of disulfiram and H
Topics: Acetaldehyde Dehydrogenase Inhibitors; Alcohol Deterrents; Aldehyde Dehydrogenase; Animals; Antineop | 2021 |
Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Copper; Disulfiram; Down-Regula | 2018 |
Copper Mediates Anti-Inflammatory and Antifibrotic Activity of Gleevec in Hepatocellular Carcinoma-Induced Male Rats.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chelating Agents; Copper; Cytokines; Disu | 2019 |
Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners.
Topics: Aldehyde Dehydrogenase; Animals; Antigens, Neoplasm; Carcinogenesis; Carcinoma, Hepatocellular; Cell | 2014 |
Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Topics: Aldehyde Dehydrogenase; Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Antineoplas | 2016 |
Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Disul | 2016 |
Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Disulfiram; Drug Carriers; Glycols; Humans; Lactic A | 2017 |
Anti-hepatocellular carcinoma properties of the anti-alcoholism drug disulfiram discovered to enzymatically inhibit the AMPK-related kinase SNARK in vitro.
Topics: Alcohol Deterrents; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; C | 2016 |
Regulation of heme synthesis and proteasomal activity by copper: possible implications for Wilson's disease.
Topics: Adenosine Triphosphatases; Carcinoma, Hepatocellular; Cation Transport Proteins; Cell Line, Tumor; C | 2009 |
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Copper; Cyclic AMP Response El | 2004 |
Effects of disulfiram on the metabolism of nitrosodiethylamine during liver carcinogenesis.
Topics: Alkylation; Animals; Biotransformation; Diethylnitrosamine; Disulfiram; DNA; Kidney; Liver; Liver Ne | 1984 |
The novel aldehyde dehydrogenase gene, ALDH5, encodes an active aldehyde dehydrogenase enzyme.
Topics: Aldehyde Dehydrogenase; Blotting, Northern; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; | 1995 |
Influence of disulfiram on the organotropy of the carcinogenic effect of dimethylnitrosamine and diethylnitrosamine in rats.
Topics: Animals; Diethylnitrosamine; Dimethylnitrosamine; Disulfiram; Esophageal Neoplasms; Liver Neoplasms; | 1976 |
On the possible mechanism of carcinogenic action of vinyl chloride.
Topics: Alkylating Agents; Animals; Disulfiram; Hemangiosarcoma; Humans; Liver Neoplasms; Mice; Neoplasms; R | 1975 |
Quantitative histochemistry of benzaldehyde dehydrogenase in hepatocellular carcinomas of vinyl chloride-treated rats.
Topics: Aldehyde Dehydrogenase; Aldehyde Oxidoreductases; Animals; Benzaldehyde Dehydrogenase (NADP+); Benza | 1986 |
Effect of various agents on liver regeneration and Walker tumor growth in partially hepatectomized rats.
Topics: Animals; Antineoplastic Agents; Benz(a)Anthracenes; Benzofurans; Carcinoma 256, Walker; Cortisone; D | 1966 |